NexImmune, Inc.
NEXI · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $2 | -$0 |
| % Margin | – | – | 89.2% | – |
| R&D Expenses | $1 | $1 | $1 | $6 |
| G&A Expenses | $2,082 | $2 | $2 | $4 |
| SG&A Expenses | $2 | $2 | -$1 | $4 |
| Sales & Mktg Exp. | -$2,080 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | -$0 |
| Operating Expenses | $4 | $3 | $1 | $10 |
| Operating Income | -$4 | -$3 | -$4 | -$10 |
| % Margin | – | – | -174.1% | – |
| Other Income/Exp. Net | $1 | -$0 | -$2 | -$2 |
| Pre-Tax Income | -$2 | -$3 | -$5 | -$10 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$3 | -$5 | -$10 |
| % Margin | – | – | -252.7% | – |
| EPS | -1.69 | -2.46 | -5.03 | -9.4 |
| % Growth | 31.3% | 51.1% | 46.5% | – |
| EPS Diluted | -1.69 | -2.46 | -5.03 | -9.4 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$3 | -$5 | -$8 |
| % Margin | – | – | -241.9% | – |